A Washington University drug discovery program, led by Michael Holtzman, MD, has received three grants totaling more than $5 million to develop new medical therapeutics for respiratory diseases. The target illnesses range from the common cold to life-threatening lung disease.
Bacteria often attack with toxins designed to hijack or even kill host cells. To avoid self-destruction, bacteria have ways of protecting themselves from their own toxins. Now, researchers have described one of these protective mechanisms, potentially paving the way for new classes of antibiotics that cause the bacteria’s toxins to turn on themselves.